西维斯健康 2026年季度报告

FORM 10-Q (Mark One)☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVS HEALTH CORPORATION(Exact name of registrant as specified in its charter) 05-0494040 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) Registrant’s telephone number, including area code:(401) 765-1500Former name, former address and former fiscal year, if changed since last report:N/A Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☑Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☑Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☑Non-accelerated filer☐ Accelerated filer☐Smaller reporting company☐Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☑No As of April29, 2026, the registrant had 1,275,927,307 shares of common stock issued and outstanding. TABLE OF CONTENTS Part IFinancial Information Item 1.Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.Exhibits Signatures Form 10-Q Table of Contents Part I.Financial Information Item 1.Financial Statements Index to Condensed Consolidated Financial Statements PageCondensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2026 and 20252Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three months ended March 31, 2026 and20253Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2026 and December 31, 20254Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2026 and 20255Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) for the three months ended March 31, 2026 and20257Notes to Condensed Consolidated Financial Statements (Unaudited)8Report of Independent Registered Public Accounting Firm31 CVS Health CorporationCondensed Consolidated Statements of Operations(Unaudited) CVS Health CorporationCondensed Consolidated Statements of Comprehensive Income(Unaudited) Three Months EndedMarch 31,In millions20262025Net income$2,957$1,782Other comprehensive income (loss), net of tax:Net unrealized investment gains (losses)(244)216Change in discount rate on long-duration insurance reserves43(33)Net cash flow hedges(4)(4)Other comprehensive income (loss)(205)179Comprehensive income2,7521,961Comprehensive income attributable to noncontrolling interests(14)(3)Comprehensive income attributable to CVS Health$2,738$1,958 CVS Health CorporationCondensed Consolidated Balance Sheets(Unaudited) CVS Health CorporationCondensed Consolidated Statements of Cash Flows(Unaudited) CVS Health CorporationCondensed Consolidated Statements of Cash Flows(Unaudited) Three Months EndedMarch 31,Inmillions20262025Reconciliation of net income to net cash provided by operating activities:Net income$2,957$1,782Adjustments required to reconcile net income to net cash provided by operating activities:Depreciation and amortization1,1151,154Stock-based compensation266126Loss on sale of subsidiary—236Deferred income taxes and other items(91)(169)Change in operating assets and liabilities, net of effects from acquisitions:Accounts receivable,